Literature DB >> 19436114

Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine.

Robert Hanczko1, David R Fernandez, Edward Doherty, Yueming Qian, Gyorgy Vas, Brian Niland, Tiffany Telarico, Adinoyi Garba, Sanjay Banerjee, Frank A Middleton, Donna Barrett, Maureen Barcza, Katalin Banki, Steve K Landas, Andras Perl.   

Abstract

Although oxidative stress has been implicated in acute acetaminophen-induced liver failure and in chronic liver cirrhosis and hepatocellular carcinoma (HCC), no common underlying metabolic pathway has been identified. Recent case reports suggest a link between the pentose phosphate pathway (PPP) enzyme transaldolase (TAL; encoded by TALDO1) and liver failure in children. Here, we show that Taldo1-/- and Taldo1+/- mice spontaneously developed HCC, and Taldo1-/- mice had increased susceptibility to acetaminophen-induced liver failure. Oxidative stress in Taldo1-/- livers was characterized by the accumulation of sedoheptulose 7-phosphate, failure to recycle ribose 5-phosphate for the oxidative PPP, depleted NADPH and glutathione levels, and increased production of lipid hydroperoxides. Furthermore, we found evidence of hepatic mitochondrial dysfunction, as indicated by loss of transmembrane potential, diminished mitochondrial mass, and reduced ATP/ADP ratio. Reduced beta-catenin phosphorylation and enhanced c-Jun expression in Taldo1-/- livers reflected adaptation to oxidative stress. Taldo1-/- hepatocytes were resistant to CD95/Fas-mediated apoptosis in vitro and in vivo. Remarkably, lifelong administration of the potent antioxidant N-acetylcysteine (NAC) prevented acetaminophen-induced liver failure, restored Fas-dependent hepatocyte apoptosis, and blocked hepatocarcinogenesis in Taldo1-/- mice. These data reveal a protective role for the TAL-mediated branch of the PPP against hepatocarcinogenesis and identify NAC as a promising treatment for liver disease in TAL deficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19436114      PMCID: PMC2689120          DOI: 10.1172/JCI35722

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  68 in total

Review 1.  WNT/beta-catenin signaling in liver health and disease.

Authors:  Michael D Thompson; Satdarshan P S Monga
Journal:  Hepatology       Date:  2007-05       Impact factor: 17.425

Review 2.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 3.  AP-1 in mouse development and tumorigenesis.

Authors:  W Jochum; E Passegué; E F Wagner
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

Review 4.  The therapeutic use of acetaminophen in patients with liver disease.

Authors:  Gordon D Benson; Raymond S Koff; Keith G Tolman
Journal:  Am J Ther       Date:  2005 Mar-Apr       Impact factor: 2.688

Review 5.  Wnt/beta-catenin signaling in cancer stemness and malignant behavior.

Authors:  Riccardo Fodde; Thomas Brabletz
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

6.  A newborn with severe liver failure, cardiomyopathy and transaldolase deficiency.

Authors:  N M Verhoeven; M Wallot; J H J Huck; O Dirsch; A Ballauf; U Neudorf; G S Salomons; M S van der Knaap; T Voit; C Jakobs
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

7.  Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression.

Authors:  K Banki; E Hutter; E Colombo; N J Gonchoroff; A Perl
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

8.  Kinetic and chemical mechanisms of the sheep liver 6-phosphogluconate dehydrogenase.

Authors:  N E Price; P F Cook
Journal:  Arch Biochem Biophys       Date:  1996-12-15       Impact factor: 4.013

9.  Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites.

Authors:  P Costantini; B V Chernyak; V Petronilli; P Bernardi
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

10.  Changes in pathways of pentose phosphate formation in relation to phosphoribosyl pyrophosphate synthesis in the developing rat kidney. Effects of glucose concentration and electron acceptors.

Authors:  M Sochor; S Kunjara; A L Greenbaum; P McLean
Journal:  J Dev Physiol       Date:  1989-09
View more
  37 in total

1.  Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling.

Authors:  Xu-Feng Zhang; Xinping Tan; Gang Zeng; Amalea Misse; Sucha Singh; Youngsoo Kim; James E Klaunig; Satdarshan P S Monga
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 2.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

Review 3.  Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase.

Authors:  Andras Perl; Robert Hanczko; Tiffany Telarico; Zachary Oaks; Steve Landas
Journal:  Trends Mol Med       Date:  2011-03-02       Impact factor: 11.951

4.  N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents.

Authors:  Ian K Lai; Kiran Dhakal; Gopi S Gadupudi; Miao Li; Gabriele Ludewig; Larry W Robertson; Alicia K Olivier
Journal:  Toxicology       Date:  2012-07-21       Impact factor: 4.221

Review 5.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

6.  Hepatocellular Carcinoma of Fibrolamellar Type in an Adolescent: Case Report and Literature Review.

Authors:  Javier Santiago-Reynoso; Karina Senyase Zamaripa-Martínez; Juan Manuel Dorantes-Loya; Guillermo J Gaytán-Fernández; Evelia Apolinar-Jiménez; Francisco Paz-Gómez; Felipe Farias-Serratos; María Maldonado-Vega
Journal:  Gastrointest Tumors       Date:  2019-05-27

7.  Novel association of early onset hepatocellular carcinoma with transaldolase deficiency.

Authors:  Charles A Leduc; Elizabeth E Crouch; Ashley Wilson; Jay Lefkowitch; Mirjam M C Wamelink; Cornelis Jakobs; Gajja S Salomons; Xiaoyun Sun; Yufeng Shen; Wendy K Chung
Journal:  JIMD Rep       Date:  2013-10-06

8.  Transaldolase deficiency: report of 12 new cases and further delineation of the phenotype.

Authors:  Wafaa Eyaid; Talal Al Harbi; Shamsa Anazi; Mirjam M C Wamelink; Cornelis Jakobs; Mohammad Al Salammah; Mohammed Al Balwi; Majid Alfadhel; Fowzan S Alkuraya
Journal:  J Inherit Metab Dis       Date:  2013-01-12       Impact factor: 4.982

9.  N-Acetylcysteine Therapy in an Infant with Transaldolase Deficiency Is Well Tolerated and Associated with Normalization of Alpha Fetoprotein Levels.

Authors:  Lance H Rodan; Gerard T Berry
Journal:  JIMD Rep       Date:  2016-04-30

Review 10.  The pentose phosphate pathway and cancer.

Authors:  Krushna C Patra; Nissim Hay
Journal:  Trends Biochem Sci       Date:  2014-07-15       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.